Huntington National Bank Has $42.62 Million Stock Position in Zoetis Inc. (NYSE:ZTS)

Huntington National Bank boosted its stake in Zoetis Inc. (NYSE:ZTS) by 4.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 261,557 shares of the company’s stock after purchasing an additional 12,310 shares during the quarter. Huntington National Bank owned about 0.06% of Zoetis worth $42,616,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Mission Wealth Management LP raised its position in shares of Zoetis by 2.0% in the 4th quarter. Mission Wealth Management LP now owns 2,938 shares of the company’s stock valued at $479,000 after buying an additional 59 shares in the last quarter. VeraBank N.A. increased its stake in Zoetis by 4.1% in the fourth quarter. VeraBank N.A. now owns 1,562 shares of the company’s stock valued at $254,000 after acquiring an additional 62 shares during the last quarter. HUB Investment Partners LLC raised its position in Zoetis by 4.7% during the fourth quarter. HUB Investment Partners LLC now owns 1,373 shares of the company’s stock valued at $224,000 after purchasing an additional 62 shares in the last quarter. Procyon Advisors LLC lifted its stake in Zoetis by 1.4% during the fourth quarter. Procyon Advisors LLC now owns 4,712 shares of the company’s stock worth $768,000 after purchasing an additional 63 shares during the last quarter. Finally, Deseret Mutual Benefit Administrators boosted its holdings in shares of Zoetis by 6.6% in the 4th quarter. Deseret Mutual Benefit Administrators now owns 1,045 shares of the company’s stock valued at $170,000 after purchasing an additional 65 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

ZTS stock opened at $161.77 on Wednesday. The firm has a market cap of $72.44 billion, a PE ratio of 29.57, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. The stock has a 50-day moving average price of $166.26 and a 200-day moving average price of $174.05. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $200.33.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. The business had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. As a group, equities research analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be paid a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 1.24%. The ex-dividend date is Monday, April 21st. Zoetis’s dividend payout ratio (DPR) is currently 36.56%.

Insider Activity

In other news, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $170.00, for a total transaction of $55,420.00. Following the transaction, the executive vice president now directly owns 15,781 shares of the company’s stock, valued at $2,682,770. This represents a 2.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Willie M. Reed sold 1,210 shares of the stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the transaction, the director now owns 11,245 shares in the company, valued at approximately $1,868,244.30. This represents a 9.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,862 shares of company stock worth $312,254. Company insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

ZTS has been the subject of a number of research analyst reports. Piper Sandler boosted their price target on Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a report on Thursday, February 27th. Barclays increased their target price on shares of Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. StockNews.com raised shares of Zoetis from a “hold” rating to a “buy” rating in a report on Friday, March 7th. Stifel Nicolaus dropped their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Finally, Morgan Stanley cut their target price on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a research report on Friday, February 14th. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $215.90.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.